-
Mashup Score: 1
AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.
Source: medcitynews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0UnitedHealth posts $5.8B in profit, $92.4B in revenue on Q3 beat - 7 month(s) ago
UnitedHealth Group kicked off another round of quarterly earnings calls Friday morning, when it reported $5.8 billion in profit for the third quarter. | UnitedHealth Group kicked off another round of quarterly earnings calls on Friday morning, where it reported $5.8 billion in profit for the third quarter.
Source: www.fiercehealthcare.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@UHC sees a 'mixed bag' of responses to #GLP1 demand | #weightloss https://t.co/eRotHbWB7i
-
-
Mashup Score: 0
GLP-1 drugs commonly used for weight loss management purposes can be a miracle solution for people who have struggled with their weight, but leaders at Solera Health say there are financial and hea | Solera Health’s step therapy program gives individuals personalized care to improve health conditions without GLP-1 drugs.
Source: www.fiercehealthcare.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@solerahealth utilizes step therapy approach before prescribing #GLP1 drugs | #weightloss https://t.co/OQdT6T0cbH
-
-
Mashup Score: 0Employers Covering Weight-Loss Drugs Could Nearly Double - 7 month(s) ago
The number of US employers who cover obesity medications, including Wegovy from Novo Nordisk that belongs to a class of GLP-1 drugs, could nearly double next year, according to a survey.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
The number of U.S. employers who cover #obesity medications, including Wegovy from Novo Nordisk that belongs to a class of #GLP1 drugs, could nearly double next year, according to a survey. https://t.co/6gJYA97Jri https://t.co/4PRmi2Az7r
-
-
Mashup Score: 0Lark Health expands digital coaching platform for obesity care amid soaring demand for GLP-1 drugs - 7 month(s) ago
Lark Health, a digital chronic condition management platform, is expanding its weight management solution for health plans and employers to help manage the surging consumer demand for pricey obesit | Lark Health is leveraging its capabilities in managing chronic conditions to offer clinical screening and prescribing of newer weight loss drugs like Ozempic and Wegovy as well as ongoing clinical management and behavior change coaching.
Source: www.fiercehealthcare.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@LarkHealth expands digital #coaching platform for #obesity care amid soaring demand for #GLP1 drugs | #chronicdisease mgmt #weightloss https://t.co/ruKvFznliS
-
-
Mashup Score: 0Abbott: Data indicates GLP-1s could be FreeStyle Libre accelerator - 7 month(s) ago
New real-world data from Abbott demonstrates a potentially positive impact of GLP-1 drugs such as Ozempic and Wegovy on diabetes tech.
Source: www.drugdeliverybusiness.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Abbott: Data indicates #GLP1 could be @FreeStyleLibre accelerator | #CGM #Diabetes #RWD https://t.co/zk8wbn97Hx
-
-
Mashup Score: 0Insulin pump-makers grapple with questions about GLP-1s - 8 month(s) ago
The new class of weight loss drugs has caused a stock selloff, but is unlikely to “meaningfully change the long-term outlook for diabetes,” analysts wrote.
Source: www.medtechdive.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Insulinpump-makers grapple with questions about #GLP1 | #weightloss #diabetes https://t.co/efxsEHvBoJ
-
-
Mashup Score: 0Analysts: GLP-1s should have minor impact on insulin pump market - 8 month(s) ago
Analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry.
Source: www.drugdeliverybusiness.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Analysts: #GLP1 drugs should have minor impact on #insulinpump market — but will boost #CGM | #diabetes #weightloss https://t.co/MrKv8ljAta
-
-
Mashup Score: 0Diabetes - 8 month(s) ago
According to the American Diabetes Association, nearly 30 million children and adults in the United States have diabetes, and 8 million of them do not know that they have the disease. Many people think that diabetes is a condition that affects only older people, but in 2012, there were 1.7 million new cases of diabetes found in people 20 or older. Diabetes is a major risk factor for heart […]
Source: www.texasheart.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Curious about the safety of GLP-1 agonists for weight loss? Dr. Postalian provides insights on using these medications to shed those extra pounds. ℹ️ Learn More-- Diabetes: https://t.co/mYGTDLbJfl Obesity and Overweight: https://t.co/wkMH4H0rj4 #GLP1 #diabetes #obesity https://t.co/qCYOF7OkwV
-
-
Mashup Score: 1Boehringer preps phase 3 for dual-action obesity drug - 9 month(s) ago
Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor dual agonist – partnered with Zealand Pharma and also known as BI 456906 – achieved up to 19% weight loss in people living with overweight or obesity in a study presented at the American Diabetes Association (ADA) congress in June. The two companies are in hot pursuit of Novo Nordisk and Eli Lilly, currently
Source: pharmaphorum.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Announcement that @Boehringer prepares for a phase 3 for dual-action #obesity drug | #pharmaphorum #GLP1 #GLP-1 agonist GLP-1 https://t.co/51HBGFNB8H
-
.@AstraZeneca had earlier efforts at developing an oral drug for weight management fell short of expectations, but in striking a deal for an early-stage compound from Eccogene, the pharma giant gains what it says could be a best-in-class molecule. #GLP1 https://t.co/LNnKYfPFOR